As global demand for new innovations in the booming 3D printing industry
grows exponentially by the day, Rainbow Coral Corp. (OTCBB: RBCC) is
preparing to capitalize with groundbreaking new products for the 3D
3D printing is such a hot industry that even top analysts are revising
their growth forecasts. Earlier this month, a Credit Suisse research
team revised the firm's 2016 projection for the 3D printing market up
357 percent, from $175 million to $800 million. In four years, Wohlers
Associates believes that the sale of 3D printing products and services
will approach $6 billion worldwide, and $10.8 billion by 2021.
Overlooked market opportunities for emerging 3D printing technology are
responsible for the revised projections. One of those overlooked
opportunities is 3D bioprinting, a revolutionary newtechnique that
involves the printing of cell-loaded replicas of human tissues for the
purposes of drug testing and regenerative medicine.
RBCC is working closely with its joint venture partner, Nano3D
Biosciences (n3D) to capitalize on the extraordinary demand for new
innovations by developing and marketing the BiO Assay, the world's first
commercially availabe 3D bioprinting system designed for high
throughput and high-content drug screening. The automated toxicity assay
uses biocompatible magnetic nanoparticles to print cells into 3D
structures much faster and more affordably than competing bioprinting
tech currently on the market.
The BiO Assay represents a revolution in pharmaceutical research,
offering better and faster results than have previously been possible.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To NFVZone's Homepage ]